Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
This study aimed to characterize the population pharmacokinetics and pharmacogenetics of ethambutol in co-infected tuberculosis/HIV adult patients. Ethambutol plasma concentrations, determined by LC-MS/MS, in 63 patients receiving ethambutol as part of a rifampicin based fixed-dose combination therapy for tuberculosis were analysed using nonlinear mixed-effects modelling. A one-compartment disposition model with first order elimination, and four transit compartments prior to first-order absorption was found to adequately describe the concentration - time profiles of ethambutol in plasma. Bodyweight was implemented as an allometric function on the clearance and volume parameters. Estimates of oral clearance and volume of distribution were 77.4 L/h and 76.2 L, respectively. G/A mutation with regard to CYP1A2 2159 G>A was associated with a 50 % reduction in relative bioavailability. Simulations revealed that 30 mg/kg and 50 mg/kg doses for G/G and G/A carriers, respectively would result in a clinically adequate exposure. The results presented here suggest that CYP1A2 polymorphism affects ethambutol exposure in this population and that current treatment guidelines may result in underexposure in patients co-infected with tuberculosis and HIV. Based on simulations, a dose increase from 15-20 mg/kg to 30 mg/kg is suggested. However, the 50 mg/kg dose required to reach therapeutic exposure in G/A carriers may be inappropriate due to the dose dependent toxicity of ethambutol. Additional studies are required to further investigate CYP450 polymorphism effects on ethambutol pharmacokinetics.